

Aminoglycosides Market Size, Share & Trends Analysis Report By Product (Neomycin, Tobramycin, Gentamicin), By Route Of Administration (Injectables, Feed, Intra-mammary), By Application (Veterinary, Skin Infection), By Region, And Segment Forecasts, 2025 - 2030

<https://marketpublishers.com/r/A40FC5DB8C29EN.html>

Date: April 2025

Pages: 105

Price: US\$ 5,950.00 (Single User License)

ID: A40FC5DB8C29EN

Abstracts

This report can be delivered to the clients within 3 Business days

Aminoglycoside Market Growth & Trends

The global aminoglycosides market size is anticipated to reach USD 2.45 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 4.34% from 2025 to 2030. This expected growth in demand can be ascribed to the increasing incidences of animal disease outbreaks leading to high utilization of antibiotics.

However, reduction in prescription rate of aminoglycoside antibiotics due to side effects associated with usage of these drugs that include severe ototoxicity, nephrotoxicity, and neuromuscular blockade are expected to affect the market growth negatively. Furthermore, regulatory disapproval for the usage of certain aminoglycoside in regions is also anticipated to attribute for subordinate growth in this industry.

Aminoglycoside Market Report Highlights

Tobramycin is expected to exhibit significant growth in the

market over the forecast period. It is a potent aminoglycoside antibiotic that plays a critical role in the global aminoglycosides industry due to its broad-spectrum efficacy against Gram-negative bacteria, particularly *Pseudomonas aeruginosa*.

Based on route of administration, the market is categorized into injectable, feed, intra-mammary, topical, oral, and injectable, led the market with a market share of 26.73% in 2024.

Skin infections are anticipated to grow at the fastest CAGR over the forecast period. Skin infections represent a significant driver for the market, owing to their high prevalence and the effectiveness of aminoglycosides in treating gram-negative bacterial infections.

The North America aminoglycosides industry held 37.60% of the global revenue share in 2024. This large share is attributed to bacterial infections, which are dominant in North America, and a well-established healthcare infrastructure affecting millions of people.

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
 - 1.2.1. Product
 - 1.2.2. Route of Administration
 - 1.2.3. Application
 - 1.2.4. Regional scope
 - 1.2.5. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
 - 1.4.1. Purchased database
 - 1.4.2. GVR's internal database
 - 1.4.3. Secondary sources
 - 1.4.4. Primary research
 - 1.4.5. Details of primary research
 - 1.4.5.1. Data for primary interviews in North America
 - 1.4.5.2. Data for primary interviews in Europe
 - 1.4.5.3. Data for primary interviews in Asia Pacific
 - 1.4.5.4. Data for primary interviews in Latin America
 - 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
 - 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
 - 1.7.1. Commodity flow analysis (Model 1)
 - 1.7.2. Approach 1: Commodity flow approach
 - 1.7.3. Volume price analysis (Model 2)
 - 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Outlook

- 2.2.1. Product and route of administration outlook
- 2.2.2. Application outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights

CHAPTER 3. AMINOGLYCOSIDES MARKET VARIABLES, TRENDS & SCOPE

- 3.1. Market Lineage Outlook
 - 3.1.1. Parent market outlook
 - 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
 - 3.2.1. Market driver analysis
 - 3.2.1.1. Increasing prevalence of bacterial infections
 - 3.2.1.2. Advancements in drug development
 - 3.2.1.3. Growing awareness and diagnosis
 - 3.2.2. Market restraint analysis
 - 3.2.2.1. High cost of development
 - 3.2.2.2. Regulatory challenges for new drug approvals
- 3.3. Aminoglycosides Market Analysis Tools
 - 3.3.1. Industry Analysis - Porter's
 - 3.3.1.1. Supplier power
 - 3.3.1.2. Buyer power
 - 3.3.1.3. Substitution threat
 - 3.3.1.4. Threat of new entrant
 - 3.3.1.5. Competitive rivalry
 - 3.3.2. PESTEL Analysis
 - 3.3.2.1. Political landscape
 - 3.3.2.2. Technological landscape
 - 3.3.2.3. Economic landscape
 - 3.3.3. Pricing Analysis
 - 3.3.4. Pipeline Analysis
 - 3.3.4.1. Phase
 - 3.3.4.2. Phase
 - 3.3.4.3. Phase

CHAPTER 4. AMINOGLYCOSIDES MARKET: TREATMENT ESTIMATES & TREND ANALYSIS

- 4.1. Global Aminoglycosides Market: Product Dashboard

- 4.2. Global Aminoglycosides Market: Product Movement Analysis
- 4.3. Global Aminoglycosides Market by Product, Revenue
- 4.4. Neomycin
 - 4.4.1. Neomycin market estimates and forecasts 2018 to 2030 (USD Million)
- 4.5. Tobramycin
 - 4.5.1. Tobramycin market estimates and forecasts 2018 to 2030 (USD Million)
- 4.6. Gentamicin
 - 4.6.1. Gentamicin market estimates and forecasts 2018 to 2030 (USD Million)
- 4.7. Amikacin
 - 4.7.1. Amikacin market estimates and forecasts 2018 to 2030 (USD Million)
- 4.8. Paromomycin
 - 4.8.1. Paromomycin market estimates and forecasts 2018 to 2030 (USD Million)
- 4.9. Streptomycin
 - 4.9.1. Streptomycin market estimates and forecasts 2018 to 2030 (USD Million)
- 4.10. Kanamycin
 - 4.10.1. Kanamycin market estimates and forecasts 2018 to 2030 (USD Million)
- 4.11. Others
 - 4.11.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 5. AMINOGLYCOSIDES MARKET: ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS

- 5.1. Global Aminoglycosides Market: Route of Administration Dashboard
- 5.2. Global Aminoglycosides Market: Route of Administration Movement Analysis
- 5.3. Global Aminoglycosides Market by Route of Administration, Revenue
- 5.4. Injectable
 - 5.4.1. Injectable monoclonal antibodies market estimates and forecasts 2018 to 2030 (USD Million)
- 5.5. Feed
 - 5.5.1. Feed market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. Intra-mammary
 - 5.6.1. Intra-mammary market estimates and forecasts 2018 to 2030 (USD Million)
- 5.7. Topical
 - 5.7.1. Topical market estimates and forecasts 2018 to 2030 (USD Million)
- 5.8. Oral
 - 5.8.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 6. AMINOGLYCOSIDES MARKET: APPLICATION ESTIMATES & TREND ANALYSIS

- 6.1. Global Aminoglycosides Market: Application Dashboard
- 6.2. Global Aminoglycosides Market: Application Movement Analysis
- 6.3. Global Aminoglycosides Market by Application, Revenue
- 6.4. Skin Infection
 - 6.4.1. Skin infection market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5. UTI & Pelvic Diseases
 - 6.5.1. UTI & pelvic diseases market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6. Veterinary
 - 6.6.1. Veterinary market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7. Respiratory diseases
 - 6.7.1. Respiratory diseases market estimates and forecasts 2018 to 2030 (USD Million)
- 6.8. Others
 - 6.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 7. AMINOGLYCOSIDES MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY TREATMENT, THERAPEUTIC CLASS, AND ROUTE OF ADMINISTRATION

- 7.1. Regional Dashboard
- 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.3. North America
 - 7.3.1. U.S.
 - 7.3.1.1. Key country dynamics
 - 7.3.1.2. Regulatory framework/ reimbursement structure
 - 7.3.1.3. Competitive scenario
 - 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
 - 7.3.2. Canada
 - 7.3.2.1. Key country dynamics
 - 7.3.2.2. Regulatory framework/ reimbursement structure
 - 7.3.2.3. Competitive scenario
 - 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
 - 7.3.3. Mexico
 - 7.3.3.1. Key country dynamics
 - 7.3.3.2. Regulatory framework/ reimbursement structure
 - 7.3.3.3. Competitive scenario
 - 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)

7.4. Europe

7.4.1. UK

7.4.1.1. Key country dynamics

7.4.1.2. Regulatory framework/ reimbursement structure

7.4.1.3. Competitive scenario

7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)

7.4.2. Germany

7.4.2.1. Key country dynamics

7.4.2.2. Regulatory framework/ reimbursement structure

7.4.2.3. Competitive scenario

7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)

7.4.3. France

7.4.3.1. Key country dynamics

7.4.3.2. Regulatory framework/ reimbursement structure

7.4.3.3. Competitive scenario

7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)

7.4.4. Italy

7.4.4.1. Key country dynamics

7.4.4.2. Regulatory framework/ reimbursement structure

7.4.4.3. Competitive scenario

7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)

7.4.5. Spain

7.4.5.1. Key country dynamics

7.4.5.2. Regulatory framework/ reimbursement structure

7.4.5.3. Competitive scenario

7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)

7.4.6. Norway

7.4.6.1. Key country dynamics

7.4.6.2. Regulatory framework/ reimbursement structure

7.4.6.3. Competitive scenario

7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)

7.4.7. Sweden

7.4.7.1. Key country dynamics

7.4.7.2. Regulatory framework/ reimbursement structure

7.4.7.3. Competitive scenario

7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)

7.4.8. Denmark

7.4.8.1. Key country dynamics

7.4.8.2. Regulatory framework/ reimbursement structure

7.4.8.3. Competitive scenario

7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)

7.5. Asia Pacific

7.5.1. Japan

7.5.1.1. Key country dynamics

7.5.1.2. Regulatory framework/ reimbursement structure

7.5.1.3. Competitive scenario

7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)

7.5.2. China

7.5.2.1. Key country dynamics

7.5.2.2. Regulatory framework/ reimbursement structure

7.5.2.3. Competitive scenario

7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)

7.5.3. India

7.5.3.1. Key country dynamics

7.5.3.2. Regulatory framework/ reimbursement structure

7.5.3.3. Competitive scenario

7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)

7.5.4. Australia

7.5.4.1. Key country dynamics

7.5.4.2. Regulatory framework/ reimbursement structure

7.5.4.3. Competitive scenario

7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)

7.5.5. South Korea

7.5.5.1. Key country dynamics

7.5.5.2. Regulatory framework/ reimbursement structure

7.5.5.3. Competitive scenario

7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)

7.5.6. Thailand

7.5.6.1. Key country dynamics

7.5.6.2. Regulatory framework/ reimbursement structure

7.5.6.3. Competitive scenario

7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)

7.6. Latin America

7.6.1. Brazil

7.6.1.1. Key country dynamics

7.6.1.2. Regulatory framework/ reimbursement structure

7.6.1.3. Competitive scenario

7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)

7.6.2. Argentina

7.6.2.1. Key country dynamics

7.6.2.2. Regulatory framework/ reimbursement structure

7.6.2.3. Competitive scenario

7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)

7.7. MEA

7.7.1. South Africa

7.7.1.1. Key country dynamics

7.7.1.2. Regulatory framework/ reimbursement structure

7.7.1.3. Competitive scenario

7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)

7.7.2. Saudi Arabia

7.7.2.1. Key country dynamics

7.7.2.2. Regulatory framework/ reimbursement structure

7.7.2.3. Competitive scenario

7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)

7.7.3. UAE

7.7.3.1. Key country dynamics

7.7.3.2. Regulatory framework/ reimbursement structure

7.7.3.3. Competitive scenario

7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)

7.7.4. Kuwait

7.7.4.1. Key country dynamics

7.7.4.2. Regulatory framework/ reimbursement structure

7.7.4.3. Competitive scenario

7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

CHAPTER 8. COMPETITIVE LANDSCAPE

8.1. Recent Developments & Impact Analysis, By Key Market Participants

8.2. Company/Competition Categorization

8.3. Vendor Landscape

8.3.1. List of key distributors and channel partners

8.3.2. Key customers

8.3.3. Key company market share analysis, 2024

8.3.4. Pfizer Inc.

8.3.4.1. Company overview

8.3.4.2. Financial performance

8.3.4.3. Product benchmarking

- 8.3.4.4. Strategic initiatives
- 8.3.5. Merck & Co. Inc.
 - 8.3.5.1. Company overview
 - 8.3.5.2. Financial performance
 - 8.3.5.3. Product benchmarking
 - 8.3.5.4. Strategic initiatives
- 8.3.6. AbbVie Inc.
 - 8.3.6.1. Company overview
 - 8.3.6.2. Financial performance
 - 8.3.6.3. Product benchmarking
 - 8.3.6.4. Strategic initiatives
- 8.3.7. Teva Pharmaceutical Industries Ltd
 - 8.3.7.1. Company overview
 - 8.3.7.2. Financial performance
 - 8.3.7.3. Product benchmarking
 - 8.3.7.4. Strategic initiatives
- 8.3.8. Cipla
 - 8.3.8.1. Company overview
 - 8.3.8.2. Financial performance
 - 8.3.8.3. Product benchmarking
 - 8.3.8.4. Strategic initiatives
- 8.3.9. Sun Pharmaceutical Industries Ltd.
 - 8.3.9.1. Company overview
 - 8.3.9.2. Financial performance
 - 8.3.9.3. Product benchmarking
 - 8.3.9.4. Strategic initiatives
- 8.3.10. Lupin
 - 8.3.10.1. Company overview
 - 8.3.10.2. Financial performance
 - 8.3.10.3. Product benchmarking
 - 8.3.10.4. Strategic initiatives
- 8.3.11. Aurobindo Pharma Limited
 - 8.3.11.1. Company overview
 - 8.3.11.2. Financial performance
 - 8.3.11.3. Product benchmarking
 - 8.3.11.4. Strategic initiatives
- 8.3.12. Fresenius Kabi
 - 8.3.12.1. Company overview
 - 8.3.12.2. Financial performance

8.3.12.3. Product benchmarking

8.3.12.4. Strategic initiatives

8.3.13. Viatris Inc.

8.3.13.1. Company overview

8.3.13.2. Financial performance

8.3.13.3. Product benchmarking

8.3.13.4. Strategic initiatives

I would like to order

Product name: Aminoglycosides Market Size, Share & Trends Analysis Report By Product (Neomycin, Tobramycin, Gentamicin), By Route Of Administration (Injectables, Feed, Intra-mammary), By Application (Veterinary, Skin Infection), By Region, And Segment Forecasts, 2025 - 2030

Product link: <https://marketpublishers.com/r/A40FC5DB8C29EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A40FC5DB8C29EN.html>